Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing proprietary pharmaceuticals that improve the treatment of cancer and other life-threatening illnesses.
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15984,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive
company featured image
  • Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel treatments for inflammatory lung diseases and cancer
  • Cantex is led by Stephen Marcus, M.D., and Neil Flanzraich, seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience



pipeline featured image
  • Current lead product, Dicopp®, targets inflammasome-driven complications of COVID-19 infection, pulmonary inflammatory diseases, and cancer
  • DSTAT, licensed to Chimerix, Inc. (NASDAQ: CMRX), is in advanced stage clinical trials for acute myeloid leukemia and COVID-19 associated acute lung injury



doctor viewing vaccine

April 2020 – Chimerix, Exclusive Licensee of Cantex’ Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19.


July 2019 – Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia.

DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)